PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE'S
ARM-002 ANTI-CANCER VACCINE

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE'S
ARM-002 ANTI-CANCER VACCINE

02.05.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

_________________________________________________________________

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE'S
ARM-002 ANTI-CANCER VACCINE

Vancouver, BC, Canada, May 1st, 2024 - Defence Therapeutics Inc. ("Defence"
or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian
biopharmaceutical company developing novel immune-oncology therapeutics and
drug delivery technologies, is pleased to announce the successful completion
of a pre-clinical vaccination trial using its ARM-002TM vaccine against
pancreatic cancer. The vaccine was shown to be therapeutically effective
against pre-established pancreatic cancer especially when combined with the
anti-PD-1 immune-checkpoint inhibitor.

In the context of an in vivo pre-clinical study, Defence tested its ARM-002TM
vaccine pulsed with a pancreatic cancer lysate in combination with the
anti-PD-1 immune-checkpoint in animals with pre-established Pan02 tumors.
Animals' follow-up revealed that the vaccine is indeed potent as all treated
animals remained alive for over 40 days (equivalent to almost 5 years in the
human scale) with tumor growth heavily impaired/blocked compared to other
treatments/controls. Since Defence is interested in targeting
"hard-to-treat" cancers, these results represent an important infliction
point and an incentive to redirect its Phase I trial using the ARM-002TM
anti-cancer vaccine to target pancreatic cancer.

Pancreatic cancer begins when uncontrolled cellular growth occurs in the
pancreas. It is rarely diagnosed at early stages when the chance of curing
the disease is the greatest as it often doesn't cause symptoms until it
metastasises to other organs. This classifies this type of cancer as a
"hard-to-treat" cancer as patients at that point face limited treatment
options.

Treatment for pancreatic cancer depends on the cancer stage as well as its
location. Although the first goal of pancreatic cancer treatment is to get
rid of the cancer, this unrealistic option often shifts to improving quality
of life and keeping the cancer from growing or causing more harm. As such,
treatments available for pancreatic cancer often involve surgery, radiation,
chemotherapy or a combination, and are associated with limited clinical
benefits or life-related complications. For instance, even if surgery to
remove the whole pancreas is performed, patients would then rely on taking
medicine their entire life to replace the hormones and enzymes made by the
pancreas. Alternatively, chemotherapy (often combined with radiation
therapy) can shrink the cancer, but it is often associated with resistance
and/or relapse. As these standards of care fail in large set of patients,
the next available option relies on immunotherapy, which uses the body's
immune system to kill cancer cells.

"Defence's goal is to bring our proprietary and innovative immune therapies
to the clinical stage for the benefit of the cancer patients. We often say
that our Accum® platform is highly versatile as it can lead to the
development of verticals promoting different products for multiple
indications. This also applies to a single product as it can be adapted to
various diseases as demonstrated with our ARM-002TM vaccine in vivo
pre-clinical studies, which was shown to impair the growth of solid T-cell
lymphoma, melanoma and now pancreatic cancer" says Mr. Plouffe, Chief
Executive Officer of Defence Therapeutics.

Pancreatic Cancer Market size is estimated to surpass USD 36 Billion by the
end of 2036, growing at a CAGR of 18% during the forecast period of
2024-2036. In 2023, the industry size of the pancreatic cancer was over USD
6 Billion. The growth of the market can be attributed to the rising
prevalence of cancer cases among people across the world.

https://www.researchnester.com/reports/pancreatic-cancer-market/5299

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology
company working on engineering the next generation vaccines and ADC products
using its proprietary platform. The core of Defence Therapeutics platform is
the ACCUM® technology, which enables precision delivery of vaccine antigens
or ADCs in their intact form to target cells. As a result, increased
efficacy and potency can be reached against catastrophic illness such as
cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking
statements". All statements in this release, other than statements of
historical facts, that address events or developments that the Company
expects to occur, are forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not
always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar
expressions, or that events or conditions "will", "would", "may", "could" or
"should" occur. Although the Company believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that
could cause the actual results to differ materially from those in
forward-looking statements include regulatory actions, market prices, and
continued availability of capital and financing, and general economic,
market or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on the
beliefs, estimates and opinions of the Company's management on the date the
statements are made. Except as required by applicable securities laws, the
Company undertakes no obligation to update these forward-looking statements
in the event that management's beliefs, estimates or opinions, or other
factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or accuracy of
this release.


---------------------------------------------------------------------------

02.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Defence Therapeutics Inc.
                   1680 - 200 Burrard St
                   V6C3L6 Vancouver
                   Canada
   E-mail:         info@defencetherapeutics.com
   Internet:       https://defencetherapeutics.com
   ISIN:           CA24463V1013
   WKN:            A3CN14
   Listed:         Regulated Unofficial Market in Frankfurt, Stuttgart;
                   Toronto
   EQS News ID:    1893577

End of News EQS News Service
---------------------------------------------------------------------------

1893577 02.05.2024 CET/CEST